COVID-19 Human Challenge Trials – What will be the Regulatory Considerations?

Objective

The current SARS-Cov-2 pandemic has brought the world to a standstill. Research groups and drug developers all over the world are scrambling to develop antivirals and vaccines to treat or prevent COVID-19. Longer term, better modeling will be required to test compounds in a controlled clinical setting once the pandemic has abated. Such a model could be a human challenge trial, commonly known as a controlled human infection model, or CHIM.

A coronavirus CHIM could be an ideal tool to support endeavors to develop effective COVID-19 interventions and provide a longer-term platform to support preparations against the emergence of new or novel coronaviruses.

This webinar will highlight the regulatory considerations to implement such a model and speed up the development pathway of much needed drugs and antiviral products.

Agenda

• Introduction to controlled human infection modeling (CHIM)
• SARS-CoV-2: an introduction
• Regulatory considerations surrounding COVID-19 modeling
• Working with regulators on COVID-19 CHIM design and development
• How a COVID-19 CHIM trial could accelerate your pipeline development
• Q&A

Language: English
Cost: No Charge

Can't Make a Live Session?

Register now and receive a complimentary recording after the live event.

For further information, please contact:

SGS United Kingdom Ltd
Life Sciences
t: +44 (0) 151 350 6666